DB:UR8

Stock Analysis Report

Executive Summary

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies.


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has UroGen Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UR8's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

22.4%

UR8

3.0%

DE Biotechs

9.1%

DE Market


1 Year Return

-45.9%

UR8

-9.5%

DE Biotechs

-13.1%

DE Market

Return vs Industry: UR8 underperformed the German Biotechs industry which returned -7.4% over the past year.

Return vs Market: UR8 underperformed the German Market which returned -14.2% over the past year.


Shareholder returns

UR8IndustryMarket
7 Day22.4%3.0%9.1%
30 Day-23.7%1.5%-1.0%
90 Day-36.2%-23.9%-20.7%
1 Year-45.9%-45.9%-9.2%-9.5%-10.6%-13.1%
3 Yearn/a17.1%15.9%-10.7%-18.1%
5 Yearn/a-8.7%-11.1%-10.7%-22.8%

Price Volatility Vs. Market

How volatile is UroGen Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is UroGen Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: UR8 (€18.2) is trading below our estimate of fair value (€130.49)

Significantly Below Fair Value: UR8 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: UR8 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: UR8 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UR8's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UR8 is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is UroGen Pharma forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

52.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: UR8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: UR8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: UR8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: UR8's revenue (51.2% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: UR8's revenue (51.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UR8 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has UroGen Pharma performed over the past 5 years?

-55.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: UR8 is currently unprofitable.

Growing Profit Margin: UR8 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: UR8 is unprofitable, and losses have increased over the past 5 years at a rate of -55.9% per year.

Accelerating Growth: Unable to compare UR8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UR8 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.9%).


Return on Equity

High ROE: UR8 has a negative Return on Equity (-58.32%), as it is currently unprofitable.


Next Steps

Financial Health

How is UroGen Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: UR8's short term assets ($148.6M) exceed its short term liabilities ($19.5M).

Long Term Liabilities: UR8's short term assets ($148.6M) exceed its long term liabilities ($2.6M).


Debt to Equity History and Analysis

Debt Level: UR8 is debt free.

Reducing Debt: UR8 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UR8 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: UR8 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -49.5% each year.


Next Steps

Dividend

What is UroGen Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate UR8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate UR8's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UR8's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UR8's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UR8's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Liz Barrett (57yo)

1.25s

Tenure

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She served as Chief Executive Officer of Novartis Oncology ...


Leadership Team

NamePositionTenureCompensationOwnership
Peter Pfreundschuh
CFO & Secretary1.67yrsUS$2.49m0.029% $112.8k
Mark Schoenberg
Chief Medical Officer2.33yrsUS$300.00k0.083% $324.0k
Gil Hakim
Consultant1.67yrsUS$3.86mno data
Gary Titus
Consultant1.83yrsUS$3.49mno data
Ron Bentsur
1.25yrsUS$5.95m0.19% $758.0k
Elizabeth Barrett
President1.25yrsno data0.58% $2.3m
Catherine Bechtold
Senior Director of Investor Relations2.25yrsno datano data
Eric Van Zanten
Senior Director of Communicationsno datano datano data
Sari Prutchi-Sagiv
Marketing Directorno datano datano data
Marina Konorty
Executive Vice President of Research & Development and Technical Operations0.083yrno datano data

1.7yrs

Average Tenure

55yo

Average Age

Experienced Management: UR8's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President1.25yrsno data0.58% $2.3m
Kathryn Falberg
Independent Director3yrsUS$540.33k0.077% $300.0k
Fred Cohen
Independent Director2.92yrsUS$525.33k0.071% $276.6k
Cynthia Butitta
Independent Director2.5yrsUS$540.96kno data
Stuart Holden
Independent Director4.33yrsUS$527.83kno data
Arie Belldegrun
Chairman of the Board17.33yrsUS$1.98m1% $3.9m
Ran Nussbaum
Independent Director6.92yrsUS$525.41kno data
Jack Baniel
Member of Scientific Advisory Boardno datano datano data
Herbert Lepor
Chairman of Scientific Advisory Boardno datano datano data
Fred Witjes
Member of Scientific Advisory Boardno datano datano data

3.0yrs

Average Tenure

63yo

Average Age

Experienced Board: UR8's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.3%.


Top Shareholders

Company Information

UroGen Pharma Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UroGen Pharma Ltd.
  • Ticker: UR8
  • Exchange: DB
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$424.157m
  • Listing Market Cap: US$390.055m
  • Shares outstanding: 21.15m
  • Website: https://www.urogen.com

Number of Employees


Location

  • UroGen Pharma Ltd.
  • 499 Park Avenue
  • New York
  • New York
  • 10014
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
URGNNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDMay 2017
UR8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 2017
0XODLSE (London Stock Exchange)YesOrdinary SharesGBUSDMay 2017

Biography

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company’s lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/09 02:20
End of Day Share Price2020/04/08 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.